Hinge Health Inc. (NYSE:HNGE) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Hinge Health Inc. (NYSE:HNGE) have been given a consensus recommendation of “Moderate Buy” by the nineteen analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $57.4667.

A number of equities analysts recently issued reports on the company. KeyCorp raised their target price on Hinge Health from $45.00 to $60.00 and gave the stock an “overweight” rating in a research note on Monday, July 14th. Citizens Jmp assumed coverage on Hinge Health in a research note on Monday, July 14th. They issued a “strong-buy” rating and a $58.00 target price for the company. Bank of America raised their target price on Hinge Health from $42.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday, August 6th. Robert W. Baird assumed coverage on Hinge Health in a research note on Friday, September 5th. They issued a “neutral” rating and a $56.00 target price for the company. Finally, Morgan Stanley raised their target price on Hinge Health from $57.00 to $67.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 23rd.

Hinge Health Stock Down 0.1%

Hinge Health stock opened at $49.52 on Friday. Hinge Health has a 1-year low of $33.42 and a 1-year high of $62.18. The stock has a fifty day simple moving average of $54.05.

Hinge Health (NYSE:HNGE) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($13.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($4.98) by ($8.12). The firm had revenue of $139.10 million during the quarter, compared to analysts’ expectations of $125.16 million. Hinge Health’s quarterly revenue was up 54.9% on a year-over-year basis. During the same period last year, the firm earned ($0.96) earnings per share. Hinge Health has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.

Hedge Funds Weigh In On Hinge Health

Institutional investors have recently modified their holdings of the stock. FNY Investment Advisers LLC purchased a new position in shares of Hinge Health during the 2nd quarter valued at about $310,000. CHURCHILL MANAGEMENT Corp purchased a new position in shares of Hinge Health during the 2nd quarter valued at about $828,000. Atika Capital Management LLC purchased a new position in shares of Hinge Health during the 2nd quarter valued at about $2,261,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Hinge Health during the 2nd quarter valued at about $966,000. Finally, Foresite Capital Management VI LLC purchased a new position in shares of Hinge Health during the 2nd quarter valued at about $6,986,000.

About Hinge Health

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.